As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

For example, EGFR 19 deletions and EGFR L858R point mutations respond well to tyrosine kinase inhibitors (TKIs), which are also called EGFR inhibitors. Drugs that target the EGFR protein and block ...

EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...

Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about CKPT stock here.

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...

In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.